Zoom: excellent DD as usual. In the last several p

Zoom: excellent DD as usual. In the last several press releases 'opthamological conditions' has appeared in the company description as a focus of their potential treatments. If they have unbelievable data for RP then it would make sense to build an opthamalogic portfolio around that strength. Didn't Bascom specifically say it was the best data they have ever seen for RP? As they generate more and more data in that space they can bring products to market faster and faster, especially if they are designated as Orphan Diseases. I can see one of the major opthamalogic focused BP companies very interested in a partnership with AMBS or one that really wants in that market.